Biohaven Completes Enrollment for Phase 2 Obesity Trial with Taldefgrobep Alfa Biohaven has completed enrollment for a Phase 2 obesity study using Taldefgrobep Alfa, aiming for significant weight loss and muscle gain.

Biohaven Completes Enrollment for Phase 2 Obesity Trial with Taldefgrobep Alfa #US #Biohaven #New_Haven #Taldefgrobep_Alfa #Obesity_Study